IL205432A0 - Method of identigfying safe nmda receptor antagonists - Google Patents

Method of identigfying safe nmda receptor antagonists

Info

Publication number
IL205432A0
IL205432A0 IL205432A IL20543210A IL205432A0 IL 205432 A0 IL205432 A0 IL 205432A0 IL 205432 A IL205432 A IL 205432A IL 20543210 A IL20543210 A IL 20543210A IL 205432 A0 IL205432 A0 IL 205432A0
Authority
IL
Israel
Prior art keywords
identigfying
receptor antagonists
nmda receptor
safe
safe nmda
Prior art date
Application number
IL205432A
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of IL205432A0 publication Critical patent/IL205432A0/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2857—Seizure disorders; Epilepsy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL205432A 2007-11-06 2010-04-29 Method of identigfying safe nmda receptor antagonists IL205432A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98592407P 2007-11-06 2007-11-06
US98592207P 2007-11-06 2007-11-06
PCT/US2008/082660 WO2009061935A2 (en) 2007-11-06 2008-11-06 Methods of identifying safe nmda receptor antagonists

Publications (1)

Publication Number Publication Date
IL205432A0 true IL205432A0 (en) 2010-12-30

Family

ID=40626437

Family Applications (1)

Application Number Title Priority Date Filing Date
IL205432A IL205432A0 (en) 2007-11-06 2010-04-29 Method of identigfying safe nmda receptor antagonists

Country Status (12)

Country Link
EP (1) EP2212694A4 (en)
JP (1) JP2011503013A (en)
KR (1) KR20100100858A (en)
CN (1) CN101918832A (en)
AU (1) AU2008323877A1 (en)
BR (1) BRPI0820406A2 (en)
CA (1) CA2704475A1 (en)
EA (1) EA201070571A1 (en)
IL (1) IL205432A0 (en)
MX (1) MX2010004971A (en)
WO (1) WO2009061935A2 (en)
ZA (1) ZA201003724B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014159960A (en) * 2011-06-08 2014-09-04 Astellas Pharma Inc Automatic measurement method for spontaneous pain action of chronic pain model animal
PT3297619T (en) * 2015-05-22 2022-08-05 Vistagen Therapeutics Inc Therapeutic uses of l-4-chlorokynurenine
WO2017093354A1 (en) 2015-11-30 2017-06-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Nmdar antagonists for the treatment of diseases associated with angiogenesis
CN111960514A (en) * 2020-08-28 2020-11-20 浙江浙能技术研究院有限公司 Electrodialysis intelligent control system and method for concentrating desulfurization wastewater

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002250256B2 (en) * 2001-03-08 2008-04-03 Emory University pH-dependent NMDA receptor antagonists
KR20030063765A (en) * 2002-01-24 2003-07-31 엘지전자 주식회사 Objective Lens for Pick Up System
UY27939A1 (en) * 2002-08-21 2004-03-31 Glaxo Group Ltd COMPOUNDS
EP1697409A1 (en) * 2003-12-16 2006-09-06 Aventis Pharmaceuticals, Inc. Secreted neural apoptosis inhibiting proteins
US20060199864A1 (en) * 2004-08-23 2006-09-07 Traynelis Stephen F Selection of pH-dependent compounds for in vivo therapy

Also Published As

Publication number Publication date
EP2212694A2 (en) 2010-08-04
WO2009061935A3 (en) 2009-08-20
KR20100100858A (en) 2010-09-15
BRPI0820406A2 (en) 2015-05-19
ZA201003724B (en) 2013-10-30
JP2011503013A (en) 2011-01-27
CN101918832A (en) 2010-12-15
AU2008323877A1 (en) 2009-05-14
EA201070571A1 (en) 2010-12-30
EP2212694A4 (en) 2011-10-12
CA2704475A1 (en) 2009-05-14
WO2009061935A2 (en) 2009-05-14
MX2010004971A (en) 2010-07-28

Similar Documents

Publication Publication Date Title
HK1244694A1 (en) Novel antagonists of the glucagon receptor
HK1182441A1 (en) Method for the detection of intracellular truncated receptors
AP2739A (en) Azaindazole compounds as CCRI receptor antagonists
ZA201001874B (en) Nmda receptor antagonists for neuroprotection
PL2927224T3 (en) Receptor antagonists
IL208895A0 (en) Nmda receptor antagonists for the treatment of neuropsychiatric disorders
EP2184278A4 (en) P2x4 receptor antagonist
EP2427430A4 (en) 5-oxo-ete receptor antagonist compounds
EP2058304A4 (en) P2x4 receptor antagonist
ZA201103156B (en) Isonicotinamide orexin receptor antagonists
EP2350024A4 (en) Improved process for the preparation of endothelin receptor antagonists
ZA201006587B (en) Methods for treating disorders using nmda nr2b-subtype selective antagonist
HK1203481A1 (en) Glucagon antagonists
EP2191830A4 (en) Solid preparation comprising npyy5 receptor antagonist
HK1149205A1 (en) Methods for inhibiting angiogenesis using egfl8 antagonists
EP2617717A4 (en) P2x4 receptor antagonist
IL200380A0 (en) Mineralcorticoid receptor antagonists for the treatment of endometriosis
IL205432A0 (en) Method of identigfying safe nmda receptor antagonists
ZA200903496B (en) Spiro-piperidine derivatives as via receptor antagonists
EP2163557A4 (en) Function-selective vitamin d receptor agonist
IL211996A0 (en) Process for the preparation of substituted phenylalanines
IL207438A0 (en) 2-aminoquinolines as 5-ht5a receptor antagonists
EP2173695A4 (en) Method for the preparation of cis-4-tert-butylcyclohexanol
EP2632253A4 (en) Process for the preparation of an orexin receptor antagonist
EP2252149A4 (en) A method for the preparation of fentanyl